发布求助
文献互助 智能选刊 最新文献

Progress in Neurology and Psychiatry最新文献

筛选
英文 中文
Risperidone in non‐epileptic attack disorder and chromosome 15q deletion syndrome 利培酮治疗非癫痫发作障碍和染色体15q缺失综合征
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.725
A. Javaid, David Kent, Joanne Bone, D. Michael
{"title":"Risperidone in non‐epileptic attack disorder and chromosome 15q deletion syndrome","authors":"A. Javaid, David Kent, Joanne Bone, D. Michael","doi":"10.1002/pnp.725","DOIUrl":"https://doi.org/10.1002/pnp.725","url":null,"abstract":"Chromosome 15q11.2 microdeletion is an emerging syndrome identified in individuals with Prader‐Willi syndrome and Angelman syndrome but also found in isolation. Here, the authors present a case of a 19‐year‐old woman with chromosome 15q11.2 microdeletion and her successful treatment with risperidone, a tailored positive behaviour support plan and with staff training around non‐epileptic attack disorder.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47865478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Melatonin as first‐line treatment for sleep disorders in Parkinson's disease? 褪黑素作为帕金森病睡眠障碍的一线治疗？
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.728
C. Cox, A. Mackett
{"title":"Melatonin as first‐line treatment for sleep disorders in Parkinson's disease?","authors":"C. Cox, A. Mackett","doi":"10.1002/pnp.728","DOIUrl":"https://doi.org/10.1002/pnp.728","url":null,"abstract":"Sleep disturbance has been reported in up to 88%–98% of Parkinson's disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behaviour disorder (RBD), which can lead to violent dream enactment behaviour, has a prevalence in Parkinson's disease of 20% to 50% but best management of the condition is unclear. Here, the authors consider whether melatonin is an effective pharmacological option to manage RBD.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47021974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electroconvulsive therapy in Huntington's disease 亨廷顿氏病的电休克疗法
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.729
A. Yahya, Shakil Khawaja
{"title":"Electroconvulsive therapy in Huntington's disease","authors":"A. Yahya, Shakil Khawaja","doi":"10.1002/pnp.729","DOIUrl":"https://doi.org/10.1002/pnp.729","url":null,"abstract":"Electroconvulsive therapy (ECT) is used in Huntington's disease (HD) for severe and life threatening forms of mental illness when other treatment options have failed or when a rapid response is required. Here, Dr Yahya and Dr Khawaja review the published literature over the last 10 years for the use of ECT in HD focusing on efficacy, safety and tolerability.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45011867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric pathology potentially induced by COVID‐19 vaccine 新型冠状病毒肺炎疫苗可能诱发的精神病理学
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.723
K. Roberts, Nittu Sidhu, Melanie Russel, Mohammed Abbas
{"title":"Psychiatric pathology potentially induced by COVID‐19 vaccine","authors":"K. Roberts, Nittu Sidhu, Melanie Russel, Mohammed Abbas","doi":"10.1002/pnp.723","DOIUrl":"https://doi.org/10.1002/pnp.723","url":null,"abstract":"Vaccines are the predominant biological management measure for controlling the COVID‐19 pandemic, and aim to break the chain between disease status and hospitalisation. Unseen or rare side‐effects are being reported via the COVID‐19‐specific Yellow Card reporting site, including mania, psychosis and encephalitis of various subtypes. This article presents a patient displaying a range of psychiatric pathologies that occurred within 10 days of AstraZeneca COVID‐19 vaccination and resolved spontaneously without antipsychotic medication. The possibility of a vaccine‐related autoimmune encephalitis (AE) is tentatively raised.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49464427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Post‐COVID‐19 acute cognitive syndromes 后COVID - 19急性认知综合征
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.731
{"title":"Post‐COVID‐19 acute cognitive syndromes","authors":"","doi":"10.1002/pnp.731","DOIUrl":"https://doi.org/10.1002/pnp.731","url":null,"abstract":"Post-COVID-19 acute cognitive syndromes Further to Gaber & Eltemamy’s report of post-COVID-19 aphantasia,1 I suggest that other apparently acute cognitive syndromes are likely to be seen post-COVID-19. A previously healthy 49-year-old woman was referred with a complaint of forgetting following confirmed COVID-19 infection 9 months earlier characterised by cough and fever but not requiring hospitalisation. Prior to this acute illness she reported her memory to be excellent, even for remote details that other family members could not recall. Because of her symptoms, she could no longer pursue her occupation of teaching. Cognitive testing and structural brain imaging disclosed no cause for her symptoms. Inconsistency between self-reported and objective performance was in keeping with a proposed operational definition of functional cognitive disorder (FCD).2 This clinical observation, which I suspect is far from unique, is problematic for metacognitive models of FCD,3 as are other instances of acute onset FCD, such as the dissociative amnesia type,4 which imply sudden rather than gradual change in synaptic neuromodulation. These entities share a clear stressful precipitating event, physical or psychological, the severity of which may be disproportionate to the subsequent cognitive symptoms. The mechanism(s) that underpin acute post-COVID-19 cognitive syndromes such as FCD remain to be determined but might include neurovascular and immunological dysfunction.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"25 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42458555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Meningovascular neurosyphilis: cognitive and neuropsychiatric impact 脑膜血管性神经梅毒：认知和神经精神影响
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-10-01 DOI: 10.1002/pnp.726
Madhusudan ( Amod) Mangesh Dalvi, O. Babatola
{"title":"Meningovascular neurosyphilis: cognitive and neuropsychiatric impact","authors":"Madhusudan ( Amod) Mangesh Dalvi, O. Babatola","doi":"10.1002/pnp.726","DOIUrl":"https://doi.org/10.1002/pnp.726","url":null,"abstract":"Neurosyphilis is commonly viewed through the prism of the pre‐penicillin era when parenchymatous neurosyphilis was seen more commonly and presented as general paresis of the insane. In the post‐antibiotic era, meningeal and vascular forms of syphilis are more commonly seen and can present as a stroke. Here, the authors present a case of a 47‐year‐old man with meningovascular neurosyphilis confirmed by CSF serology who presented with cognitive, mood, psychosis, gait changes and sudden‐onset severe vertigo indicative of syphilitic apoplexy.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44784793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digest 消化
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-09-17 DOI: 10.1002/pnp.252
ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson
{"title":"Digest","authors":"ZáNean D. McClain, Erin Snapp, Daniel Tindall, Jill Anderson","doi":"10.1002/pnp.252","DOIUrl":"https://doi.org/10.1002/pnp.252","url":null,"abstract":"Perampanel (Fycompa), an AMPAtype glutamate receptor antagonist, developed by Eisai has been launched as the first in a new class of treatment for uncontrolled partial epilepsy. It is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44182203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digest 消化
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-06-24 DOI: 10.1002/pnp.4
K. Gammage, J. Caron, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf
{"title":"Digest","authors":"K. Gammage, J. Caron, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf","doi":"10.1002/pnp.4","DOIUrl":"https://doi.org/10.1002/pnp.4","url":null,"abstract":"It is unusual for small studies to have much of an impact but an East London team made the national news after paying non‐adherent patients to have their depot injections (Psychiatric Bull 2007;31:4‐7).","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"11 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41505160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digest 消化
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-06-10 DOI: 10.1002/pnp.448
ZáNean D. McClain, Jill Pawlowski, Daniel Tindall
{"title":"Digest","authors":"ZáNean D. McClain, Jill Pawlowski, Daniel Tindall","doi":"10.1002/pnp.448","DOIUrl":"https://doi.org/10.1002/pnp.448","url":null,"abstract":"Ending summer time increases depression","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"20 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48204711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digest 消化
IF 1.2
Progress in Neurology and Psychiatry Pub Date : 2021-05-05 DOI: 10.1002/pnp.182
K. Gammage, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf
{"title":"Digest","authors":"K. Gammage, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf","doi":"10.1002/pnp.182","DOIUrl":"https://doi.org/10.1002/pnp.182","url":null,"abstract":"Antidepressant weight gain Anti ‐ depressants are another class of drugs associated with weight gain but a new meta‐analysis of 116 studies identifies some that carry the greatest risk (J Clin Psychiatry 2010;71:1259‐72). Amitriptyline, mirtazapine and paroxetine were associated with the highest risk of weight gain whereas bupropion and acute use of fluoxetine were associated with weight loss. Evidence for other agents was inconclusive.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":"14 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pnp.182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49032591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信